Inhibitor Therapeutics Inc (INTI)

[db7]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
September 8, 2014
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
HedgePath Pharmaceuticals, Inc.
File No. 1-13467 - CF#31308
_____________________
HedgePath Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on June 30, 2014.
Based on representations by HedgePath Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:
Exhibit 10.4 through June 24, 2024
Exhibit 10.6 through June 24, 2017
Exhibit 10.8 through September 3, 2023
For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:
Kevin M. O’Neill
Deputy Secretary